Ignite Creation Date:
2025-12-25 @ 12:26 AM
Ignite Modification Date:
2026-03-05 @ 7:06 PM
Study NCT ID:
NCT03543358
Status:
COMPLETED
Last Update Posted:
2021-01-05
First Post:
2018-05-21
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Long-Term Study of Rovalpituzumab Tesirine
Sponsor:
AbbVie
Organization:
Study Overview
Official Title:
A Multicenter, Long-Term, Rollover Extension Study of Rovalpituzumab Tesirine
Status:
COMPLETED
Status Verified Date:
2020-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
True
If Expanded Access, NCT#:
NCT03503890
Has Expanded Access, NCT# Status:
NO_LONGER_AVAILABLE
Acronym:
None
Brief Summary:
The purpose of this long-term, extension study is to provide ongoing safety and efficacy follow-up of subjects who participated in a rovalpituzumab tesirine study that has completed the primary analysis and that is closing.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: